These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 7773222)

  • 1. Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma.
    Mendoza E; Territo M; Schiller G; Lill M; Kunkel L; Wolin M
    Bone Marrow Transplant; 1995 Feb; 15(2):299-303. PubMed ID: 7773222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
    Dann EJ; Daugherty CK; Larson RA
    Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
    Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
    Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology.
    van Besien KW; Mehra RC; Giralt SA; Kantarjian HM; Pugh WC; Khouri IF; Moon Y; Williams P; Andersson BS; Przepiorka D; McCarthy PL; Gajewski JL; Deisseroth AB; Cabanillas FF; Champlin R
    Am J Med; 1996 Mar; 100(3):299-307. PubMed ID: 8629675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma.
    Bernard M; Dauriac C; Drénou B; Leberre C; Branger B; Fauchet R; Le Prisé PY; Lamy T
    Bone Marrow Transplant; 1999 Feb; 23(4):329-33. PubMed ID: 10100576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
    Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up.
    Juckett M; Rowlings P; Hessner M; Keever-Taylor C; Burns W; Camitta B; Casper J; Drobyski WR; Hanson G; Horowitz M; Lawton C; Margolis J; Peitryga D; Vesole D
    Bone Marrow Transplant; 1998 May; 21(9):893-9. PubMed ID: 9613781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
    Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF
    Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Allogeneic transplantation in malignant lymphoma].
    Stötzer OJ; Schleuning M; Ledderose G; Hiddemann W; Kolb HJ
    Dtsch Med Wochenschr; 2001 Sep; 126(39):1062-9. PubMed ID: 11602913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma.
    Shepherd JD; Barnett MJ; Connors JM; Spinelli JJ; Sutherland HJ; Kingemann HG; Nantel SH; Reece DE; Currie CJ; Phillips GL
    Bone Marrow Transplant; 1993 Dec; 12(6):591-6. PubMed ID: 8136743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma.
    de Lima M; van Besien KW; Giralt SA; Khouri IF; Mehra R; Andersson BS; Przepiorka D; Gajewski JL; Korbling M; Champlin RE
    Bone Marrow Transplant; 1997 Jan; 19(2):121-7. PubMed ID: 9116608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
    van Besien K; Thall P; Korbling M; Pugh WC; Khouri I; Mehra R; Giralt S; Anderlini P; Amin K; Mirza N; Seong D; Gajewski J; Hester J; Andersson B; Cabanillas F; Champlin R; Przepiorka D
    Biol Blood Marrow Transplant; 1997 Aug; 3(3):150-6. PubMed ID: 9310192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.
    Philip T; Armitage JO; Spitzer G; Chauvin F; Jagannath S; Cahn JY; Colombat P; Goldstone AH; Gorin NC; Flesh M
    N Engl J Med; 1987 Jun; 316(24):1493-8. PubMed ID: 3295541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
    Cooney JP; Stiff PJ; Toor AA; Parthasarathy M
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):177-82. PubMed ID: 12652468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.
    Soiffer RJ; Freedman AS; Neuberg D; Fisher DC; Alyea EP; Gribben J; Schlossman RL; Bartlett-Pandite L; Kuhlman C; Murray C; Freeman A; Mauch P; Anderson KC; Nadler LM; Ritz J
    Bone Marrow Transplant; 1998 Jun; 21(12):1177-81. PubMed ID: 9674848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful allogeneic bone marrow transplantation for early relapse after autologous bone marrow transplantation in two cases of aggressive high-grade non-Hodgkin's lymphoma.
    Moreau P; Méchinaud F; Mahé B; Le Tortorec S; Rapp MJ; Maisonneuve H; Harousseau JL; Milpied N
    Bone Marrow Transplant; 1996 Sep; 18(3):665-7. PubMed ID: 8879639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.